Lab to Market Advisory

One development journey. Multiple critical decisions.

MedRyge Lab to Market Advisory helps organisations connect scientific innovation with development strategy, clinical execution, regulatory planning and evidence generation. The objective is not simply to move a product into a study, but to build a coherent pathway from early scientific potential to evidence that can support development, approval, adoption and lifecycle decisions.

Lab to market advisory across the development journey

Early Development

Development strategy
Target Product Profile
Clinical-entry planning
Evidence-gap assessment
Proof-of-concept strategy
Initial development assumptions

Clinical Development

Clinical Development Plan
Phase I–III strategy
Protocol and endpoint strategy
Operational feasibility
Country strategy
Evidence-generation planning

Execution

CRO selection
Study governance
Clinical operations
Data
Quality
Risk management
Clinical technology
Cross-functional oversight

Registration Readiness

Data readiness
Inspection readiness
Clinical evidence-gap review
Regulatory-support planning
Study close-out
Evidence traceability

Market & Lifecycle

Phase IV
Real-world evidence
Registries
Observational research
Patient/HCP studies
Post-approval evidence and lifecycle strategy

Lab to Market outcome

Move from scientific potential to a development pathway that is strategically coherent, operationally executable and evidence-driven.

Typical Lab to Market questions we help answer

What evidence is required at each stage of development?
What should the Target Product Profile and Clinical Development Plan prioritise?
Can the proposed clinical programme realistically be executed in the intended countries and sites?
Which endpoints and assessments are scientifically meaningful and operationally feasible?
What should be outsourced, what should remain sponsor-owned, and how should oversight be structured?
Where are the evidence, data, quality or regulatory gaps that could delay the next development milestone?
What post-marketing or real-world evidence will strengthen the product’s lifecycle evidence base?

Start a conversation

Next Clinical Execution Assurance Also Specialist Advisory